木瓜直播

The FDA accepted a for empagliflozin (Jardiance) as a treatment for heart failure independent of left ventricular ejection fraction in patients with or without diabetes based on the phase III EMPEROR-Preserved trial, Boehringer Ingelheim and Eli Lilly announced.

Bariatric surgery -- either Roux-en-Y gastric bypass or sleeve gastrectomy -- was associated with a significantly lower risk of in patients with nonalcoholic steatohepatitis (NASH) and obesity. (JAMA)

Intuity Medical announced that its with 10-test cartridge technology is now available in the U.S.

The FDA granted , an investigational oral treatment of hyperuricemia in patients with gout and advanced chronic kidney disease, Allena Pharmaceuticals announced.

The (ICER) released a new draft evidence report comparing the effectiveness and value of the investigational dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes.

reduced the risk of COVID-related death and ICU admission, even in patients with diabetes. However, it increased the risk of glycemic complications by over 22 times. "We now feel confident using dexamethasone for patients with diabetes in the future, just with the caveat that it may result in a short-term worsening of their condition," said study author Victoria Salem, MBBS, PhD, of Imperial College Healthcare NHS Trust in London. (Metabolism, Obesity and Diabetes)

announced a new Excellence in Clinical Endocrinology Leadership (ExCEL) program aimed at providing training to minority early career physicians.

Questions have been raised over payments to Donna Ryan, MD, , from companies that sold or were developing prescription weight-loss treatments. (STAT+, subscription required)

Comment